Avid Bioservices Inc (CDMO)

[freethemice]

I would agree with you. The abraxane trial had PS-0 60% PS-1 40%. Both trials treated
only metastatic patients. That trial still only resulted in a 1.8 month increase in MOS,
or a 27% increase, and a HR of 0.72.
Here I used SPSS to simulate a trial which would have the same MOS values and HR as the
Peregrine Bavi trial.This would also be consistent with the fact that the PS 2
patients would die off very quickly and reduce the MOS, that may be also why the MOS of
the control arm is very low also. It will be very interesting to see the subgroup data
for the Peregrine trial. Hopefully the PS 0/1 group would do much better.